Hedia Appoints New Board Member from the Pharmaceutical Industry
Hedia continues to strengthen its commercial expertise ahead of launching an updated version of the Hedia Diabetes Assistant in the UK and Sweden. The company has welcomed Kamilla Enggaard Have, the Managing Director of Jazz Pharmaceuticals Nordics, to its board. With a newly acquired MDR certification and a strategic partnership with the U.S.-based company Glooko, which has integrated Hedia into its digital platform, Hedia is positioned strongly for further growth.
“As part of our expansion, it’s crucial to bolster the commercial expertise within our board, and we’re delighted that Kamilla has accepted the position,” said CEO Lars Christian Lund. “Kamilla brings extensive international commercial experience in the diabetes field, along with scientific expertise from leading pharmaceutical companies.”
As Managing Director at Jazz Pharmaceuticals Nordics, Kamilla Have has led the establishment of the global biopharma company’s Nordic division. She previously spearheaded the global launch of Ozempic® at Novo Nordisk and worked in joint ventures with Takeda and Sanofi.
Kamilla Enggaard Have says:
“I look forward to contributing to Hedia’s international growth, drawing from my experience in the pharmaceutical industry, where I’ve seen how digital solutions can bring significant improvements for people with diabetes while easing the workload for healthcare professionals.”
